Baylor College of Medicine Research Contributes to FDA Approval of First Oral PCSK9 Inhibitor
July 17, 2026
July 17, 2026
HOUSTON, Texas, July 17 -- The Baylor College of Medicine posted the following news:
* * *
Baylor College of Medicine Research Contributes to FDA Approval of First Oral PCSK9 Inhibitor
*
Baylor College of Medicine researchers played a key role in the clinical development of the first oral PCSK9 inhibitor approved by the U.S. Food and Drug Administration. This novel therapy reduces LDL cholesterol, the bad cholesterol, in adults with hypercholes . . .
* * *
Baylor College of Medicine Research Contributes to FDA Approval of First Oral PCSK9 Inhibitor
*
Baylor College of Medicine researchers played a key role in the clinical development of the first oral PCSK9 inhibitor approved by the U.S. Food and Drug Administration. This novel therapy reduces LDL cholesterol, the bad cholesterol, in adults with hypercholes . . .